Month: June 2025

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

Written by Customer Service on June 26, 2025. Posted in Earnings Releases And Operating Results.

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® at medical conferences and a planned KOL event MDNA11 continues to exhibit compelling deep and durable anti-tumor activity in difficult-to-treat solid tumors with best-in-class potential relative to competing IL-2 programs Results presented at the 2025 AACR showed response rates in the 30-50% range in various tumor cohorts amongst high dose patients with tumor types being enrolled in Phase 2 Three cancer patients treated with MDNA11 remain tumor free since achieving complete resolution of all target and non-target lesions MDNA11 Phase 2b development plan to be solidified by end of calendar year, including evaluation of strategies for accelerated...

Dimensional Fund Advisors Ltd. : Form 8.3 – WAREHOUSE REIT PLC – Ordinary Shares

Written by Customer Service on June 26, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION (a) Full name of discloser: Dimensional Fund Advisors Ltd. in its capacity as investment advisor and on behalf its affiliates who are also investment advisors (”Dimensional”). Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Warehouse...

Orion’s FY’25 Gross Margin Increased to 25.4% (+230 bps) on Revenue of $79.7M; Expects 5% Revenue Growth and Improved Bottom Line Performance in FY’26; Call Today at 10am ET

Written by Customer Service on June 26, 2025. Posted in Public Companies.

MANITOWOC, Wis., June 26, 2025 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations, and maintenance services solutions, today reported results for its fourth quarter (Q4’25) and fiscal year ended March 31, 2025 (FY’25) and initiated a fiscal 2026 (FY’26) revenue outlook of approximately $84M, representing growth of 5% over FY’25. Orion will hold an investor call today at 10:00 a.m. ET – details below. Q4 Summary Full Year Summary Prior Three Quarters$ in millions except per share figures Q4’25 Q4’24 Change FY 2025 FY 2024 Change Q3’25 Q2’25 Q1’25LED Lighting Revenue $10.9 $16.3 -33% $47.7 $61.1 -22% $13.2 $10.8 $12.8EV Charging Revenue $5.8 $4.9 +18% $16.8 $12.3 +37% $2.4 $4.7 $3.8Maintenance...

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Written by Customer Service on June 26, 2025. Posted in Public Companies.

Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study No evidence of tachyphylaxis was observed in this study over the 6-week period Management to Host Webcast and Conference Call Today at 8:00 A.M. ETRESEARCH TRIANGLE PARK, N.C., June 26, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive topline results from VEGA-3, its second pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia....

Blue Moon Awards Mining Contract for the Construction of the Portal and Exploration Decline for Its Blue Moon Mine in Mariposa County, California

Written by Customer Service on June 26, 2025. Posted in Public Companies.

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company”) (TSXV: MOON; OTCQB: BMOOF), is pleased to announce the award of a contract to Small Mine Development, L.L.C. (“SMD”) for the construction of a portal and decline to enable underground mineral exploration activities at the Blue Moon volcanogenic massive sulphide (“VMS”) deposit (the “Project”), located in Mariposa County, California. This construction work represents a significant step forward for the Project’s development, as the portal and decline will provide access for infill and exploration drilling, and allow for further studies and investigations related to geology, rock mechanics, underground mining conditions, and metallurgical test work and ultimately to a mine commercialization decision. Blue Moon undertook a formal request...

DSV – H1 2025 analyst conference call

Written by Customer Service on June 26, 2025. Posted in Public Companies.

We expect to release the H1 2025 interim results of DSV A/S in the morning of 31 July 2025. A webcast and conference call will be held at 11:00 am CEST. At the conference call, Jens H. Lund, Group CEO, and Michael Ebbe, Group CFO, will present the H1 2025 Interim Financial Report. The presentation will be followed by a Q&A session. Date: 31 July 2025Time: 11:00 am CEST To attend the webcast presentation, please go to Webcast presentation – DSV Interim Financial Report H1 2025 or go to https://investor.dsv.com/. If you wish to ask questions during the conference call, please register through this link: Conference call Q&A – DSV Interim Financial Report H1 2025. You will receive an email with dial-in telephone numbers. We recommend participants to dial in 10 minutes prior to the scheduled...

Nature’s Sunshine Products, Inc. Announces Pricing of Secondary Public Offering of Common Stock

Written by Customer Service on June 26, 2025. Posted in Public Companies.

LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) — Nature’s Sunshine Products, Inc. (NASDAQ: NATR) (“Nature’s Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions. The Selling Stockholder will receive all of the net proceeds from the offering. Nature’s Sunshine is not selling any shares of common stock in the offering and will not receive any proceeds from the offering. The Selling Stockholder will pay any underwriting discounts and commissions...

FTAI Aviation Ltd. Announces Timing of Second Quarter 2025 Earnings and Conference Call

Written by Customer Service on June 26, 2025. Posted in Public Companies.

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) — FTAI Aviation Ltd. (NASDAQ: FTAI; the “Company” or “FTAI”) plans to announce its financial results for the second quarter 2025 after the closing of Nasdaq on Tuesday, July 29, 2025. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company’s website, https://www.ftaiaviation.com/. In addition, management will host a conference call on Wednesday, July 30, 2025 at 8:00 A.M. Eastern Time. The conference call may be accessed by registering via the following link https://register-conf.media-server.com/register/BI1c535d79815a4f5c936d9220ef1246d0. Once registered, participants will receive a dial-in and unique pin to access the call. A simultaneous webcast of the conference call will be available to the public on a...

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Written by Customer Service on June 26, 2025. Posted in Public Companies.

71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated results to be presented at ESMO GI on July 2nd Company to host investor event on July 8th ROCKVILLE, Md., June 26, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of ESMO Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) abstract #388MO related to positive data from a Phase 1b study evaluating givastomig in combination with nivolumab and mFOLFOX6 chemotherapy for metastatic gastric cancers. An objective response...

Acuity Reports Fiscal 2025 Third-Quarter Results

Written by Customer Service on June 26, 2025. Posted in Earnings Releases And Operating Results.

Strong Performance Delivers Sales Growth in Both Lighting and Intelligent SpacesDelivered Net Sales of $1.2B, an Increase of 22% Compared to the Prior Year Delivered Operating Profit of $140M, Down 4 % Compared to the Prior Year; Grew Adjusted Operating Profit to $222M, Up 33% Compared to the Prior Year Delivered Diluted EPS of $3.12, Down 14% Compared to the Prior Year; Grew Adjusted Diluted EPS to $5.12, Up 23% Compared to the Prior YearATLANTA, June 26, 2025 (GLOBE NEWSWIRE) — Acuity Inc. (NYSE: AYI), (“Acuity”), a market-leading industrial technology company, delivered net sales of $1.2 billion in the third quarter of fiscal 2025 ended May 31, 2025, an increase of $210.5 million, or 21.7 percent, compared to the prior year. “We delivered strong performance in the third quarter of fiscal 2025,” stated...

Month: June 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals